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Background: Cancer stem cells (CSC) are believed to play a crucial role in cancer recurrence due to their resistance
to conventional chemotherapy and capacity for self-renewal. Recent studies have reported that salinomycin, a
livestock antibiotic, selectively targets breast cancer stem cells 100-fold more effectively than paclitaxel. In our study
we sought to determine the effects of salinomycin on head and neck squamous cell carcinoma (HNSCC) stem cells.
Methods: MTS and TUNEL assays were used to study cell proliferation and apoptosis as a function of salinomycin
exposure in JLO-1, a putative HNSCC stem cell culture. MTS and trypan blue dye exclusion assays were performed
to investigate potential drug interactions between salinomycin and cisplatin or paclitaxel. Stem cell-like phenotype
was measured by mRNA expression of stem cell markers, sphere-forming capacity, and matrigel invasion assays.
Immunoblotting was also used to determine expression of epithelial-mesenchymal transition (EMT) markers and Akt
phosphorylation. Arrays by Illumina, Inc. were used to profile microRNA expression as a function of salinomycin
dose.
Results: In putative HNSCC stem cells, salinomycin was found to significantly inhibit cell viability, induce a 71.5%
increase in levels of apoptosis, elevate the Bax/Bcl-2 ratio, and work synergistically with cisplatin and paclitaxel in
inducing cell death. It was observed that salinomycin significantly inhibited sphere forming-capability and repressed
the expression of CD44 and BMI-1 by 3.2-fold and 6.2-fold, respectively. Furthermore, salinomycin reduced invasion
of HNSCC stem cells by 2.1 fold. Contrary to expectations, salinomycin induced the expression of EMT markers Snail,
vimentin, and Zeb-1, decreased expression of E-cadherin, and also induced phosphorylation of Akt and its
downstream targets GSK3-β and mTOR.
Conclusions: These results demonstrate that in HNSCC cancer stem cells, salinomycin can cause cell death and
decrease stem cell properties despite activation of both EMT and Akt.
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Cancer stem cells (CSCs) are a unique subpopulation
within a tumor that have the ability to self-renew and
differentiate, making them responsible for initiating and
maintaining tumors [1-3]. One of the main threats of
CSCs is that they are resistant to conventional cancer
treatments including chemotherapy and radiotherapy.
Standard cancer treatments are effective in killing the
bulk of the tumor but spare the CSCs, thereby progres-
sively increasing the fraction of CSCs in the tumor [4].
The mortality of cancer remains high because conven-
tional therapies often fail to eradicate the CSC popula-
tion, allowing relapse to occur. Therefore, a complete
cure for cancer likely involves treatments that can effect-
ively eliminate CSCs along with the bulk of the tumor.
In a recent study, Gupta et al. used a high throughput
screening to identify drugs that could potentially be used
to target breast CSCs. By using a novel method of
screening, approximately 16,000 compounds were evalu-
ated for their ability to eradicate breast CSCs. This
screening revealed that the compound salinomycin was
able to kill breast CSCs 100-fold more effectively than
paclitaxel [5]. Commonly, salinomycin is a monocar-
boxylic polyether antibiotic used to prevent coccidiosis
in poultry. As an antibiotic, salinomycin functions in dif-
ferent biological membranes as an ionophore with a high
specificity for potassium [6,7]. The antibiotic properties
of salinomycin are well known, but its potential to eradi-
cate CSCs in other cancer types needs to be further
elucidated.
The epithelial-mesenchymal transition (EMT) has long
been linked to the invasive properties of cancer stem
cells. It is a key developmental process where immotile
epithelial cells acquire mesenchymal properties and dis-
play an increased motility. It is commonly characterized
by a down-regulation of E-cadherin, a critical cell-to-cell
adhesion molecule [8]. An induction of EMT is directly
associated with activation of the PI3K/Akt pathway, as
activation of Akt has been shown to down-regulate E-
cadherin in part through stabilization of the transcrip-
tional repressor Snail [9,10]. Akt is a serine/threonine
protein kinase that plays a central role in cell prolifera-
tion, growth, and survival. Akt is often found to be con-
stitutively active in many forms of cancer, and is
responsible for the anti-apoptotic properties of carcin-
omas [11]. Glycogen synthase kinase-3 (GSK3-β) and
mTOR, two immediate downstream targets of Akt kin-
ase activity, have previously been implicated as media-
tors of EMT [5,12-14].
Recent studies have shown that epithelial cells under-
going EMT acquire critical stem-cell characteristics such
as the ability to self-renew [15]. Furthermore, Gupta
et al. used EMT-induced breast cancer stem cells in the
screening that discovered salinomycin; breast cancercells having undergone shRNA-mediated knock-down of
E-cadherin expression displayed an increased proportion
of CD44high/CD24low cells, increased resistance to che-
motherapeutic drugs, and enhanced sensitivity to salino-
mycin [5]. Of particular significance in the context of
our study, Basu et al. demonstrated that salinomycin tar-
gets mesenchymal-like cell populations within advanced-
stage HNSCC. This mesenchymal subpopulation was
characterized as having elevated resistance to the EGFR
inhibitor cetuximab and the chemotherapeutic drugs
paclitaxel and cisplatin, thus demonstrating increased
drug resistance, a characteristic of cancer stem cells. The
observed resistance to cisplatin in vitro and in primary-
tumor derived xenografts was not present for salinomy-
cin. [16].
The purpose of the present study was to extend our
understanding of salinomycin’s therapeutic properties in
head and neck squamous cell carcinoma (HNSCC) stem
cells. We aim to determine whether salinomycin, alone
and in combination with conventional chemotherapeutic
agents, effectively induces apoptosis in HNSCC stem
cells, and to further investigate its effects on cancer stem
cell properties including invasion, EMT, BMI-1 expres-
sion, CD44 expression and sphere formation. CD44 and
BMI-1 regulate self-renewal and have been established
as CSC markers in HNSCC [17]. In addition, the effect
of salinomycin on Akt signaling has not been previously
examined in any cancer type. The results of this study
demonstrate the ability of salinomycin to target head
and neck cancer stem cells, and further examines its
effects on EMT and Akt.
Methods
Ethics statement
Cultures used in this study (JLO-1) were derived in ac-
cordance with the policy and procedures of Hospital
Donosita, San Sebastion, Spain. Tissue was obtained an-
onymously and all data were analyzed anonymously
throughout the study, thus no patient consent was
obtained. Hospital Donostia, San Sebastian approved this
procurement of tissue including the waiver of consent.
Cell lines and cell cultures
JLO-1 is a putative cancer stem cell culture derived an-
onymously from a fresh laryngeal tumor of patients
undergoing resection of their cancer. Stem cell selective
cultivation conditions for JLO-1 have been described in
our previous study [18]. Briefly, flow cytometry was per-
formed to select for CD44+ cells, which were then
grown on laminin-coated plates and cultured in kera-
tinocyte serum-free media (Invitrogen, Carlsbad, CA)
containing 2 mM L-glutamine (Invitrogen), 50 μg/mL
gentamycin (Invitrogen), and 20 ng/mL EGF and FGF
(R&D Systems, Minneapolis, Minnesota) supplemented
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10% CO2.
The established HNSCC cell lines UMSCC-10B, HN-
1, and HN-30 were used in this study. UMSCC-10B was
a kind gift from Dr. Tom Carey, University of Michigan,
and HN-1 and HN-30 were gifts from Dr. J.S. Gutkind,
National Institute for Dental and Craniofacial Research.
Cell lines were routinely cultured in DMEM supplemen-
ted with 10% fetal bovine serum (FBS), 2% streptomycin
sulfate (Invitrogen), and 2% L-glutamine (Invitrogen),
and incubated at 37°C in 5% CO2 and 21% O2.
Chemicals and antibodies
Salinomycin was obtained from MP Biomedicals, LLC
(Solon, OH), and a 1 mM stock solution was prepared
in 100% ethanol. Prior to cell treatment, working con-
centrations of salinomycin were prepared in culture
media. Control groups were treated with an equal vol-
ume of ethanol vehicle. Cisplatin and paclitaxel were
purchased from Sigma-Aldrich (St. Louis, MO). Rabbit
polyclonal Bax, Rabbit polyclonal Bcl-2, Rabbit poly-
clonal p-Akt (Ser473), rabbit monoclonal vimentin
(D21H3) XP, rabbit monoclonal p-GSK3β (Ser9), rabbit
polyclonal p-mTOR (Ser2448), and rabbit polyclonal
total ERK antibodies were from Cell Signaling (Beverly,
MA). Rabbit polyclonal Snail antibody was obtained
from Abcam (Cambridge, MA).
Flow cytometry
Flow cytometry was used to confirm the CD44+ popula-
tion of the putative head and neck cancer stem cell
population. Cells were trypsinized and incubated with
anti-human CD44-APC antibody (BD Biosciences) or a
non-specific IgG antibody as a negative control.
Cell proliferation assay
MTS assays were performed using the CellTiter 96 Aque-
ous non-radioactive cell proliferation assay (Promega,
Madison, WI). Cells were trypsinized, counted, and
replated into a 96-well plate at 5000 cells per well. Cells
were allowed to adhere overnight. To generate a dose–
response curve for salinomycin, indicated doses of sali-
nomycin were added to the corresponding wells for an
incubation period of 48 hours. For synergistic assays in-
volving the combination of cisplatin and salinomycin,
cells were treated with 4 μM of salinomycin for 48 hours
followed by co-treatment with cisplatin at a range of
doses (1, 2, 5, 10, 20 μM) for an additional 48 hours. For
synergistic assays involving the combination of paclitaxel
and salinomycin, cells were treated with 0.5 μM of sali-
nomycin for 48 hours followed by co-treatment with
paclitaxel at a range of doses (1, 2, 3, 4, 6, 8 nM) for an
additional 48 hours. Each permutation was performed in
triplicates. Following the indicated incubation periods forthe above assays, 20 μL of the MTS reagent was added
into each well followed by a 1–3 hour incubation period.
The plates were then read at an absorbance of 490 nm.
Combination index analysis of drug interactions
To determine whether the observed cytotoxic inter-
actions of salinomycin with paclitaxel/cisplatin were
synergistic, additive, or antagonistic in nature, the com-
bination index (CI) method of Chou and Talalay was
used [19]. The CI value is a quantitative measure indicat-
ing the type of interaction between two drugs: CI <1
indicates synergism, CI = 1 indicates an additive effect,
and CI > 1 indicates antagonism. The CI value for each
experimental group was calculated using the following
formula: CI = (D)1/(D)2 + (Dx)1/(Dx)2, where (D)1 and
(D)2 in the numerator are the concentrations of drug 1
and 2 required in combination to produce a survival of
x%, and (Dx)1 and (Dx)2 in the denominator are the
concentrations of drug 1 and 2 required to individually
produce a survival of x%.
Trypan blue dye exclusion assay
In order to confirm the observed synergy between sali-
nomycin and cisplatin/paclitaxel, a trypan blue exclusion
assay was performed for the combination treatment
which generated the lowest CI value (indicative of the
greatest synergy) and produced a survival of less than
80%. Cells were pre-treated with indicated doses of sali-
nomycin (4 μM for cisplatin + salinomycin combination
treatments and 0.5 μM for paclitaxel + salinomycin com-
bination treatments) followed by co-treatment with
paclitaxel (3 nM) or cisplatin (5 μM) for an additional
48 hours. Media was replenished following initial salino-
mycin pre-treatment. Cell viability for each experimental
group was then determined by the percentage of cells
that excluded the dye, as trypan blue only traverses the
membrane of dead cells. Cells were mixed with an equal
volume of 0.4% trypan blue dye, and allowed to incubate
for 5 minutes. The percentage of trypan blue positive
cells was then determined by manually counting the
stained fraction with a hemocytometer.
TUNEL assay
Cells were treated with salinomycin 4 days prior to fix-
ing in 70% Ethanol. Media and growth factors were not
replenished throughout the treatment. Using the APO-
BRDUTMKit (Phoenix Flow Systems, Inc., San Diego,
CA), the cells undergoing apoptosis were labeled with
bromolated deoxyuridine triphosphate nucleotides
(BrdUTP). These cells were then identified and binded
to a fluorescein labeled antiBrdU monoclonal antibody.
After the required incubation times, the samples ana-
lyzed for the proportion of apoptotic cells by flow
cytometry.
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The cultured cells were treated with salinomycin (0 –
8 μM) for 48 hours. Total cell lysate was collected and
mRNA was extracted using the RNeasy kit (QIAGEN).
cDNA was then synthesized from 1.5 μg of total mRNA
using reverse transcriptase (Invitrogen, Carlsbad, CA,
USA), as per the manufacturer’s instructions. Real-time
quantitative PCR was performed by combining 2.5 μl of
the RT with 22.5 μl of SYBR green (Roche, Basel, Switzer-
land). The reaction was run using System 7300 (Applied
Biosystems, Foster City, CA, USA) and results were ana-
lyzed by the relative quantity method. Experiments were
performed in triplicates with GAPDH expression as the en-
dogenous control. Primers were custom designed by the
authors and created by Operon Biotechnologies,
Alabama, USA. The following sequences were used:
GAPDH forward: 50-CTTCGCTCTCTGCTCCTCC-30
GAPDH reverse: 50-CAATACGACCAAATCCGTTG-30
CD44 forward: 50-ACACCACGGGCTTTTGACCAC-30
CD44 reverse: 50-AGGAGTTGCCTGGATTGTTGCTTG-
30 BMI-1 forward: 50-TCCACAAAGCACACACATCA-30
BMI-1 reverse: 50-CTTTCATTGTCTTTTCCGCC-30 Snail
forward: 50-CTGCCCTGCGTCTGCGGAAC-30 Snail re-
verse: 50-GCTTCTCGCCAGTGTGGGTCC-30 E-Cadherin
forward: 50-CTGATGTGAATGACAACGCC-30 E-
Cadherin reverse: 50-TAGATTCTTGGGTTGGGTCG-30
ZEB-1 forward: 50-GCCGCTGTTGCTGATGTGGCT-30
ZEB-1 reverse: 50-TCTTGCCCTTCCTTTCCTGTGTCA-30
ALDH1A1 forward: 50-CGCCAGACTTACCTGTCCTA-30
ALDH1A1 reverse 50-GTCAACATCCTCCTTATCTCCT-30
Oct-4 forward: 50-GCAAAGCAGAAACCCTCGTGC-30
Oct-4 reverse: 50-ACCACACTCGGACCACATCCT-30
Nanog forward: 50-GATTTGTGGGCCTGAAGAAA-30
Nanog reverse: 50-TTGGGACTGGTGGAAGAATC-30.
Tumor sphere formation assay
The putative cancer stem cell cultures were plated at a
density of 500 cells/ml in a low-adhesion tissue culture
plate. Serum free media containing 25 ng/ml growth fac-
tors (1/5th normal growth factor concentration) was
used. Salinomycin was added when the cells were plated
at concentrations of 0, 0.5, 1, 2, 4, 8 μM. Salinomycin
was re-added every other day for 10 days and on day 10
the spheres were photographed. Media and growth fac-
tors were not replenished throughout the assay. Spheres
were plated and counted in quadruplicates.
Invasion assay
Inserts with 8 μm pores (BD Biosciences) were coated
with Matrigel from EHS murine sarcoma (Sigma), at a
concentration of 3 mg/mL. Cells were pretreated with
their respective concentrations of salinomycin for 4 days
and 100,000 viable cells of each permutation were added
to their respective inserts. To ensure that perceivedchanges in invasion were not due to cytotoxicity of sali-
nomycin, an MTS was performed for JLO-1 cells under
the same conditions as the Salinomycin-treated cells.
Cell numbers were then adjusted according to the MTS
data to account for discrepancies in cell death by using
the following formula: (100,000)/(x) = (% cell viability)/
(100), where (x) = number of cells added into each insert
and (% cell viability) is determined by the MTS (i.e., treat-
ment with 4 μM resulted in% cell viability of 33.0%; thus
303,030 cells were added into their respective inserts.).
Each permutation was performed in triplicates. Cells were
left to invade for 48 hours under hypoxic conditions (5%
O2). After 48 hours, cells were fixed for 2 minutes in
100% methanol and then stained in crystal violet. Cells
that invaded were counted in a pre-determined field.
Western blot analysis
Respective doses of salinomycin were added to the cells
48 hours before harvesting. Cells were lysed on ice for
10 minutes with RIPA buffer (0.1 M Tris, 2% SDS, 20%
glycerin, and protease inhibitor tablets from Roche Diag-
nostics, Indianapolis, IN). Gel electrophoresis using 10%
NuPage Bis-Tris gels separated the proteins, which were
then transferred onto a PVDF membrane. The membrane
was blocked for one hour in 5% non-fat dry milk in TBST
and incubated overnight in primary antibody at a dilution
of 1:1,000. The membranes were then incubated in their
appropriate secondary antibodies at a dilution of 1:10,000
and each specific protein was visualized using SuperSignal
West Pico Luminol (Pierce, Rockford, IL).
MicroRNA profiling
MicroRNA was isolated using the mirVana miRNA iso-
lation kit (Ambion, Austin, TX), following the manufac-
turer’s instructions. Samples were run on the Illumina
MicroRNA Array Profiling platform [20]. Analyses were
performed using BRB-ArrayTools developed by Dr.
Richard Simon and BRB-ArrayTools development team.
Clustering algorithms were performed by Cluster 3.0
and visualized with TreeView (Eisen Lab, Stanford
University). The data discussed in this study have been
deposited in NCBI’s Gene Expression Omnibus [21] and
are accessible through GEO Series accession num-
ber GSE33196 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE33196). Candidate microRNAs were
identified and confirmed by RT-qPCR with microRNA-
specific forward primers and a universal reverse pri-
mer. U6 small nuclear RNA transcript served as the
normalization signal. The sequences of RT-qPCR primers
for microRNA detection were as follows: hsa-mir-328: 50-
CTGGCCCTCTCTGCCCTTCCGT-30 hsa-mir-203: 50-
GTGAAATGTTTAGGACCACTAG-30 hsa-mir-199a-3p:
50-ACAGTAGTCTGCACATTGGTTA-30 Universal reverse:
50-GCGAGCACAGAATTAATACGACT-30 U6 forward:
Kuo et al. BMC Cancer 2012, 12:556 Page 5 of 14
http://www.biomedcentral.com/1471-2407/12/55650-GGGGACATCCGATAAAATTGG-30 U6 reverse: 50-
ACCATTTCTCGATTTGTGCGT-30.
Data analysis
Results represent mean and SD where appropriate.
Experiments were performed in duplicate (western blot
and TUNEL) or triplicate.
Results
Acquisition of a cancer stem cell culture
A putative cancer stem cell culture, JLO-1, was derived
from a fresh laryngeal cancer tissue. Cells were cultured
for several months under conditions that favored theNonspecific IgG PE 
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UMSCC-10B (Fig. 1B). ALDH1A1 expression of JLO-1
relative to two additional HNSCC cell lines was assessed
for further verification (Fig. 1B).
Salinomycin induces a dose-dependent increase in cell
death
To determine the effects of salinomycin on the HNSCC
stem cells, an MTS assay was performed to measureTUNEL FITC-A
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http://www.biomedcentral.com/1471-2407/12/556strand breaks, which correspond to the levels of apop-
tosis caused by salinomycin. At 2 μM, there was a sub-
stantial increase in the proportion of CSCs undergoing
apoptosis compared to the control (Fig. 2B). Western
blot analysis revealed increasing protein levels of pro-
apoptotic bax and constant levels of anti-apoptotic bcl-2
upon salinomycin treatment, indicating a dose-
dependent increase in the Bax/Bcl-2 ratio and greater
mitochondrial permeabilization (Fig. 2C). Our results
are consistent with those of Basu et al. suggesting salino-
mycin effectively kills treatment-resistant malignant sub-
populations in HNSCC [16].
Salinomycin synergistically increases cell death in
combination with cisplatin and paclitaxel
Since salinomycin shows promise as a novel treatment
for cancer, we sought to determine which chemotherapy
drugs would be beneficial for concurrent treatment. We
tested the synergy between salinomycin and two conven-
tional chemotherapy drugs for HNSCC: cisplatin and0 
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population more efficiently than either drug alone, al-
though paclitaxel exhibits markedly greater synergism
than cisplatin.
Salinomycin decreases stem cell markers and self-renewal
capabilities
To determine if salinomycin also causes a decrease in
stem cell capabilities, a RT-qPCR was performed to
quantify the change in gene expressions of the known
markers BMI-1 and CD44 were measured. CD44 is a
well-documented cell surface marker for head and neck
cancer and BMI-1 is necessary for self-renewal. Using
the same range of doses, the results showed a dose-
dependent decrease of CD44 and BMI-1, both of which
are critical for maintaining tumorigenicity in head and
neck CSCs (Fig. 4A). To confirm these effects, a sphere
formation assay was performed. The ability to form
spheres is a defining feature and indicator of CSCs. Sali-
nomycin was added during sphere formation, and the
substantial decrease in number of spheres formed con-
firms that salinomycin inhibits self-renewal of CSCs. At
the highest doses (4 μM and 8 μM) no spheres were
formed (Fig. 4B and C).
Salinomycin induces EMT but decreases invasive abilities
The ability to invade and metastasize is a characteristic
of CSCs that is often enabled by EMT. Recent studies
have even shown a direct link between an induction of
EMT and a gain in stem cell properties such as self-re-
newal. Therefore, we sought to determine the effects of
salinomycin on EMT by examining the changes in the
known regulatory markers E-cadherin, Zeb-1, Snail, and
vimentin. Contrary to our hypothesis, salinomycin
caused an induction of EMT. As shown by RT-qPCR,
there is a substantial increase in expression of Snail and
Zeb-1 and decrease in epithelial marker E-cadherin
(Fig. 5A-C). Immunoblotting verified the increase in
Snail and further established the induction of EMT by
indicating an increase in the mesenchymal marker
vimentin. (Fig. 5D). In addition, treatment with 2 μM
salinomycin resulted in the acquisition of a spindle-
shaped cell morphology (Fig. 5E). As induction of EMT
was accompanied by increasing amounts of cell death,
we speculated whether the observed EMT was simply an
epiphenomenon triggered by significant cell death as
opposed to a salinomycin-specific response. To exclude
this possibility, JLO-1 was treated with cytotoxic levels
of a control drug (one that does not influence EMT at
non-cytotoxic doses), and changes in EMT genes were
assessed. Cell death was shown to have marginal to
no effect on EMT in JLO-1 cells (Additional File 1).
Given the surprising activation of EMT, an invasion
assay was then performed to further assess the effect ofsalinomycin on migration. Interestingly, in disconnect
with the induction of EMT, salinomycin caused a dose-
dependent decrease in number of cells migrating
through a matrigel membrane (Fig. 5F).
Vimentin
Snail
Total Erk
0 µM 2 µM 4 µM
D
0 
0.25 
0.5 
0.75 
1 
1.25 
Control 0.5 µM 1 µM 2 µM 
F
o
ld
 C
h
an
g
e 
o
f 
In
va
d
ed
 C
el
ls
 
Salinomycin Concentration 
F
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0 µM 1 µM 2 µM 4 µM 8 µM 
Salinomycin Concentration 
0 
1 
2 
3 
4 
5 
6 
7 
0 µM 0.5 µM 1 µM 2 µM 4 µM 8 µM 
Salinomycin Concentration 
1 
2 
4 
8 
16 
32 
64 
0 M 1 M 2 M 4 M 8 M 
Salinomycin Concentration 
E-cadherin Snail Zeb-1
A B C
F
o
ld
 C
h
an
g
e 
in
 m
R
N
A
 E
xp
re
ss
io
n
Control 2µM Salinomycin
E
Figure 5 Salinomycin induces EMT but decreases invasive properties. (A-C) The RT-qPCR data shows a decrease gene expression in
E-cadherin and an upregulation of Snail and Zeb-1 as labeled, which correspond to an induction of EMT. All data is relative to the control of
0 μM salinomycin and endogenous control GAPDH. (D) Western blotting confirms the induction of Snail and shows an upregulation of the
mesenchymal marker vimentin. (E) Micrographs of JLO-1 upon treatment with 2 μM salinomycin depicts alterations in cell morphology. (F) The
graph denotes the fold change in number of cells that invaded through a matrigel membrane relative to the control of 0 μM salinomycin. Error
bars represent standard deviation.
Kuo et al. BMC Cancer 2012, 12:556 Page 9 of 14
http://www.biomedcentral.com/1471-2407/12/556Salinomycin induces phosphorylation of Akt
The activation of the PI3K/Akt pathway has been shown
to be a central feature of EMT. This signaling pathway is
often found overly active in many cancers, which nega-
tively influences prognosis. In search of an explanation
and further verification of the unanticipated increase in
EMT markers, we investigated the effects of salinomycin
on Akt. Consistent with our EMT results, salinomycin
caused an increase in phosphorylation of Akt (Fig. 6).
Activated Akt has been shown to result in the inhibition
of Bax and up-regulation of Bcl-2, in contrast toFigure 2C. Thus, to verify that phosphorylation of Akt in
fact correlated with increased kinase activity, we investi-
gated the phosphorylation status of two immediate
downstream effectors implicated in EMT, GSK3-β and
mTOR. Previous studies have identified Snail as a direct
target of active (unphosphorylated Ser-9) GSK3-β,
resulting in inhibition of snail transcription and promo-
tion of snail degradation [12,13]. Immunoblotting
revealed increased phosphorylation of GSK3-β and
mTOR. Taken together, our findings indicate that the in-
duction of EMT follows an increase in activation of Akt,
P-Akt
Total Erk
0 µM 2 µM 4 µM
P-mTOR
P-GSK3ß
Salinomycin Concentrations
Figure 6 Salinomycin induces phosphorylation of Akt. Western
blotting shows an increase in phosphorylation of Akt (Ser473), as
well as the immediate downstream targets GSK3-β (Ser9) and mTOR
(Ser2448), when treated with the indicated doses of salinomycin.
Total Erk is utilized as a loading control.
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http://www.biomedcentral.com/1471-2407/12/556but the levels of cell death caused by salinomycin are in-
dependent of this anti-apoptotic pathway.
Salinomycin induces changes in microRNA Expression
MicroRNAs have gained widespread attention for their
roles in regulating many aspects of cancer progression
including EMT, invasion and stem cell properties. To
determine whether the effect of salinomycin could po-
tentially be mediated by microRNA activity, we per-
formed a microarray analysis of global microRNA
expression in JLO-1 cells treated with increasing doses
of salinomycin. Clustering analysis revealed a set of
microRNAs that were consistently up or down-regulated
by salinomycin, suggesting that the effects of salinomy-
cin may potentially be mediated through changes in
microRNA expression (Figure 7a). Among these micro-
RNAs were miR-328 and miR-199a-3p (Figure 7b), both
with known roles in promoting drug sensitivity [24-26].
Interestingly, salinomycin downregulated the expression
of miR-203, which is known to inhibit EMT [27].
Discussion
The CSC-inhibiting activity of salinomycin has previ-
ously been demonstrated in a variety of tumors includ-
ing those of the breast, lung, and colon. Here we have
extended these studies by showing that salinomycin
induces apoptosis and chemosensitivity while inhibiting
cell proliferation, invasion, stem cell marker expression
and sphere formation in putative HNSCC stem cells. Ul-
timately, these results suggest that salinomycin or its
derivatives may be an effective novel treatment for
HNSCC, especially when administered in combination
with standard treatments. Our results are consistent with
a previous study by Busa et al. reporting the ability of sal-
inomycin to eradicate treatment-resistant phenotypes inHNSCC. However, Basu et al. report no observed syner-
gistic efficacy between salinomycin and cisplatin in
HNSCC in vitro, speculating a possible overlap of the in-
dividual drugs’ cytotoxic mechanisms [16]. Although the
method of quantifying drug interactions is not specified,
we are not surprised by this finding given the relatively
weak synergy observed between cisplatin and salinomy-
cin in JLO-1. In contrast, combination treatment of
paclitaxel with salinomycin resulted in strong synergy for
all tested drug ratios, emphasizing the potential of this
drug pair in the treatment of HNSCC. Salinomycin was
also observed in our system to activate Akt signaling and
induce changes in gene expression indicative of EMT.
These results are quite unusual and potentially worri-
some given that Akt signaling and EMT are both heavily
implicated in cell proliferation, invasion and acquisition
of CSC properties.
At this time of writing there appears to be no other
study which documents the effect of salinomycin on
Akt, leaving open for investigation whether salinomycin
also activates Akt in other cancers. Drugs including cis-
platin, etoposide, doxorubicin, and tamoxifen have been
shown to induce Akt phosphorylation leading to che-
moresistance in some cancers [28-30]. Similarly, it is
possible that pro-survival mechanisms within HNSCC
stem cells activate Akt in the presence of salinomycin in
attempt to overcome drug-induced cell death. Further
investigation is required to elucidate the mechanisms
that are responsible for drug-induced phosphorylation.
What is clear, however, is that salinomycin is ultimately
capable of inducing apoptosis and inhibiting cell prolif-
eration in HNSCC stem cells. Since apoptosis occurs
despite the activation of Akt, it is likely that salinomycin
targets apoptotic pathways that are downstream of Akt.
We report an induction of Bax and constant expression
of Bcl-2 in salinomycin-treated JLO-1 despite increased
Akt kinase activity. Previous studies have also shown
that salinomycin is capable of inducing apoptosis
through a variety of targets including Bcl-2, P-glycopro-
tein, 26S proteasome, calpain and cytochrome C, all of
which are downstream or independent of Akt [31].
EMT has been nearly synonymous with the acquisition
of an invasive and metastatic phenotype and its link to
cancer stem cell properties is also becoming well-
established [15,32]. Furthermore, salinomycin was origin-
ally identified as a cancer stem cell inhibitor by screening
for drugs with specific toxicity against mesenchymally
transdifferentiated breast cancer cells [5]. Likewise, Basu
et al. demonstrated in vivo depletion by salinomycin of
the vimentin-positive subpopulation and enrichment of
the E-cadherin-positive subpopulation in primary tumor-
derived xenografts, possibly through selective cytotox-
icity, promotion of MET, or inhibition of EMT [16].
Thus, it is interesting that salinomycin induces gene
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Figure 7 Salinomycin induces changes in microRNA expression. (A) Heatmap derived from microarray data showing sets of microRNAs up-
or down-regulated by salinomycin. (B) Three candidate microRNAs identified by microarray were further verified via RT-qPCR. Data is shown as
the mean results of two separate experiments.
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http://www.biomedcentral.com/1471-2407/12/556expression changes indicative of EMT in HNSCC stem
cells, especially while inhibiting invasion and stemness.
This surprising observation requires a reassessment of
the link between EMT and cancer stem cells, and
strongly suggests that EMT may not in all cases lead to
an invasive or stem cell-like phenotype.
Although this study marks the first instance in which
salinomycin is shown to induce EMT, it is not the first
to show a disconnection between EMT and stem cells.
In fact, it is well known that embryonic stem cells
(ESCs) resemble epithelial cells and have high expression
of E-cadherin, which is crucial for pluripotency in ESCs
and may even be used in place of Oct-4 during somatic
cell reprogramming [33]. It is also well established that
the reverse of EMT, mesenchymal-epithelial transition
(MET), is a critical step for reprogramming mouse fibro-
blasts to induced pluripotent stem cells (iPSCs) [34,35].
In terms of cancer, it was recently demonstrated that
prostate cancer stem cells are characterized by high E-
cadherin expression, are highly invasive, and exhibit high
expression of stem cell markers Oct-3/4 and Sox2 com-
pared to cells with low E-cadherin expression [36,37]. It
has been hypothesized that cancer stem cells possess a
high degree of plasticity, and that following EMT, E-
cadherin expression may be restored without losing stem
cell function or invasive capacity [36].
Further research is required to reconcile the apparent
inconsistency between contexts in terms of the relation-
ship between EMT and stemness. Contrary to the data
presented here, a previous report has confirmed the abil-
ity of salinomycin to reverse EMT in colorectal cancer
[38]. Thus, whether salinomycin promotes or inhibits
EMT varies between cases and may be highly dependent
on cell type. In any case, the data presented here make it
clear that EMT does not always correspond to stem cell
phenotype or invasion, and that salinomycin may induce
loss of stemness through pathways that are independent
of EMT.
Investigating changes in microRNA expression may
offer additional insight into the mechanism of salinomy-
cin. In particular, microRNAs have previously been
shown to regulate invasion via EMT-independent path-
ways [39]. MiR-328 has been shown to negatively regu-
late the expression of ABCG2 in human cancer cells,
while miR-199a-3p has been shown to induce cell cycle
arrest, reduce invasion, and increase doxorubicin sensi-
tivity by negatively regulating mTOR and c-Met [25,26].
Interestingly, we report an increase in activation of
mTOR upon salinomycin treatment despite induction ofmiR-199a-3p. However, it is known that individual
microRNAs can target multiple components within one
signaling pathway. MiR-199a-3p has also been shown to
inhibit proliferation by negatively regulating the cancer
stem cell marker CD44 [24]. The upregulation of these
miRs may explain some of the effects of salinomycin in-
cluding the downregulation of CD44, decrease in inva-
sion, and the synergy observed between salinomycin and
cisplatin or paclitaxel. The ability of salinomycin to in-
duce EMT in HNSCC stem cells may be explained by
the dose-dependent downregulation of miR-203, which
has been shown to inhibit EMT in prostate cancer [27].
Further characterization of these microRNAs and other
potential pathways affected by salinomycin will provide a
greater understanding of how to target cancer stem
cells.
Conclusions
The results of this study lend promise to the notion of
targeting cancer stem cells with small molecules. Con-
sistent with a prior study in breast cancer, we have
shown that salinomycin induces apoptosis and chemo-
sensitivity while inhibiting cell proliferation, invasion,
stem cell marker expression and sphere formation in pu-
tative HNSCC stem cells. Microarray analysis revealed
that increased chemosensitivity could potentially be
mediated through changes in certain microRNA levels.
Contrary to the above effects and to current understand-
ing of cancer stem cell biology, salinomycin also acti-
vated Akt signaling and induced changes in gene
expression indicative of an EMT. This can be worrisome
if the purpose of this drug is to inhibit proliferation and
invasion/metastasis. Thus, a more complete understand-
ing of the biological effects of salinomycin is a prerequis-
ite to translating this compound or potential derivatives
for use in a clinical setting. In addition, there is a poten-
tial need to re-investigate the relationship between stem
cell phenotype, EMT and Akt signaling.
Additional file
Additional File 1: Format: PDF. Cell death does not significantly alter
expression of EMT and stem cell genes in JLO-1. A drug control was used
to confirm that dose-dependent induction of EMT genes and repression
of stem cell genes was not a mere epiphenomenon of cell death
accompanying salinomycin treatment. We have previously discovered
that Metformin does not influence EMT in JLO-1 cells at non-cytotoxic
doses, indicating it does not regulate EMT in JLO-1 (unpublished data).
(A) An MTS assay was initially performed to determine the cytoxicity
curve for JLO-1 cells treated with Metformin for 72 hours. (B) At non–
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qPCR data of Snail and E-cadherin transcript levels, thus it is an
appropriate drug control to induce cell death in JLO-1. (C) Upon 48-hour
treatment of JLO-1 with 15 mM Metformin to induce approximately 60%
cell death (equivalent to the cell death observed from 4 μM salinomycin
treatment), expression of EMT genes Snail and E-cadherin showed only
minor changes. In addition, CD44 expression was not effected by
induction of cell death.Abbreviations
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